ProQR Shares Gain 62% on Stellar Results in Phase 1/2 Usher Syndrome Trial
Source: Streetwise Reports  (3/25/21)
ProQR Therapeutics shares reached a new 52-week high after the company reported highly positive results from its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. More >

Biopharma to Request U.S. Emergency Use Authorization for COVID-19 Vaccine in April
Source: Streetwise Reports  (3/24/21)
Catalysts expected in 2021-2022 regarding Ocugen's pipeline therapeutics are discussed in a ROTH Capital Partners report. More >

Rritual Superfoods Hits the Superhighway to Nationwide Distribution and Impressive Share Gains
Source: Knox Henderson for Streetwise Reports  (3/24/21)
Knox Henderson delves into the value proposition behind Rritual Superfoods, which has just started trading this month. More >

Aptose Biosciences Shares Rise 55% on Q4 Financial Results and Promising Clinical Trials
Source: Streetwise Reports  (3/24/21)
Aptose Biosciences Inc. shares traded 55% higher after the company posted Q4 and FY/20 financial results and provided an update on the status of its drug candidates in ongoing clinical trials investigating treatments for life threatening hematologic cancers. More >

Mental Health Firm Partners with Merck on Treatment-Resistant Depression Trial
Source: Streetwise Reports  (3/22/21)
Novamind Inc. reported it is teaming up with Merck to conduct a new Phase 2a study addressing treatment-resistant depression at a key clinical research site owned by its subsidiary company Cedar Clinical Research. More >

The Covid-19 Issue Too Many Are Ready to Overlook, and the Investing Opportunity It Creates
Source: KSS, MD, PhD, for Streetwise Reports  (3/22/21)
Have we forgotten about good Covid 19 Therapeutics? KSS MD PhD, editor-in-chief of PubBio.co, discusses three gems investors should know about. More >

Clovis Oncology Shares Rise on Positive Data from Phase 3 Ovarian Cancer Trial
Source: Streetwise Reports  (3/19/21)
Shares of Clovis Oncology Inc. traded 55% higher after it reported that in the Phase 3 ARIEL4 study Rubraca (rucaparib) significantly improved progression-free survival versus chemotherapy in patients with later-line ovarian cancer associated with a BRCA Mutation. More >

Biopharma Advances Alcohol-Associated Hepatitis Trial, Receives Analgesia Drug Approval
Source: Streetwise Reports  (3/17/21)
These corporate events and the Q4/20 financials of DURECT are summarized in an H.C. Wainwright & Co. report. More >

Pharma Developer to Release Topline Data from Phase 2b COVID-19 Trial by Month-End
Source: Streetwise Reports  (3/16/21)
Algernon Pharmaceuticals reported that it expects to release topline results from the Phase 2b portion of its multinational Phase 2b/3 COVID-19 Ifenprodil study sometime during the last week of March 2021. More >

Oncternal Therapeutics Shares Trade Higher After Firm Reports 39% Growth in FY20 Grant Revenue
Source: Streetwise Reports  (3/12/21)
Oncternal Therapeutics shares traded 18% higher after the company reported Q4/20 and FY/20 financial results showing higher revenues from grants and improved operating expense without incurring any reductions in Research and Development activities. More >

Vir Shares Head Higher as Phase 3 COVID-19 Trial with GSK Achieves 85% Reduction in Hospitalization and Death
Source: Streetwise Reports  (3/11/21)
Vir Biotechnology shares traded 30% higher after the company together with its development partner GlaxoSmithKline reported that in the Phase 3 COMET-ICE trial VIR-7831 was shown to reduce hospitalization and risk of death in early treatment of adults with SARS-CoV-2. More >

Biopharma Begins Phase 2 COVID Clinical Trial
Source: Streetwise Reports  (3/10/21)
An update on two of Can-Fite BioPharma's studies involving its lead drug candidate Piclidenoson is provided in a Dawson James report. More >

Amgen Offers $1.9 Billion to Acquire Five Prime Therapeutics
Source: Streetwise Reports  (3/4/21)
Five Prime Therapeutics shares traded 78% higher after the company reported it entered into a definitive agreement to be acquired by biotech giant Amgen for $38 per share in cash. More >

U.S. Biopharma Making a 'Bold Move into a Large Market Opportunity'
Source: Streetwise Reports  (3/3/21)
This latest undertaking of Dicerna Pharmaceuticals and the near-term catalysts of some of its other programs are described in an H.C. Wainwright & Co. report. More >

Biopharma Chooses Firm to Co-Conduct Psychedelic Dose Trial
Source: Streetwise Reports  (3/2/21)
Algernon Pharmaceuticals aims to begin the study as soon as it receives the drug from the manufacturer. More >

Pandion Shares Trade Up 134% on $1.85 Billion Acquisition by Merck
Source: Streetwise Reports  (2/25/21)
Pandion Therapeutics shares reached a new 52-week high after the company reported it agreed to be acquired by pharmaceutical giant Merck & Co. in an all cash transaction for $60 per share. More >

Company's Antibiotic-Free Livestock Feed Product Shows Positive Results in Subclinical Mastitis Dairy Trial
Source: Streetwise Reports  (2/22/21)
Avivagen Inc. reported that data from a New Zealand OxC-betaTâ„¢ Livestock Dairy Trial for use against sub-clinical mastitis has been published in a top-tier international veterinary science journal. More >

Regenerative Medicine Firm Reports Positive Chronic Lower Back Pain Trial Results
Source: Streetwise Reports  (2/17/21)
New study data and next steps for Mesoblast's MPC-06-ID are presented in a Dawson James Securities report. More >

Nektar Therapeutics Planning Phase 2/3 Studies with Merck and SFJ Pharma for Head and Neck Cancer
Source: Streetwise Reports  (2/17/21)
Nektar Therapeutics shares traded 14% higher after the company reported it plans to conduct a Phase 2/3 study of bempegaldesleukin in combination with Merck's KEYTRUDA® in patients with squamous cell carcinoma of the head and neck and is partnering on a second Phase 2/3 study with SFJ Pharmaceuticals that will provide $150 million to fund development. More >

Pharma Developer Contemplates Adding Lung Scarring as Key Endpoint in Phase 2b/3 COVID-19 Trial
Source: Streetwise Reports  (2/12/21)
Algernon Pharmaceuticals reported it is considering adding "lung scarring" as an additional primary endpoint to its Phase 2b/3 COVID-19 Ifenprodil study protocol. More >

ImmunoGen Shares Rise 30% After Firm Reports FY20 Earnings and 2021 Outlook
Source: Streetwise Reports  (2/12/21)
Shares of ImmunoGen Inc. reached a new 52-week high after the company announced Q4/20 and FY/20 business operating and financial results. More >

AC Immune Reports 'Positive Interim Results' from Novel Phase 1b/2a Alzheimer's Vaccine Trial
Source: Streetwise Reports  (2/11/21)
Shares of AC Immune SA traded 15% higher after the firm reported that interim results from the Phase 1b/2a Alzheimer's trial of its ACI-35.030 vaccine demonstrated generation of potent anti-phospho-Tau antibody responses in 100% of older patients with early Alzheimer's disease. More >

Pharmaceutical Developer Hires Laboratory to Conduct Preclinical Studies of Psychedelic Compound DMT
Source: Streetwise Reports  (2/10/21)
Algernon Pharmaceuticals entered into an agreement with Charles River Laboratories, "a recognized world leader for pre-clinical neurological studies," to conduct preclinical studies for psychedelic compound DMT in stroke patients. More >

Drug Repurposer Ventures into New Area, Use of Psychedelic in Stroke
Source: Streetwise Reports  (2/5/21)
This clinical program of Algernon Pharmaceuticals and upcoming catalysts regarding its in-progress COVID-19 and chronic cough trials are discussed in a Mackie Research Capital Corp. report. More >

Coverage Initiated on Firm Developing Gold Nanoparticle Therapy for Neurological Diseases
Source: Streetwise Reports  (2/5/21)
The reasons Clene is a compelling investment are outlined in a ROTH Capital Partners report. More >